---
title: "MiNK Therapeutics 將發佈公司最新動態及 2025 年第一季度財務報告"
description: "紐約，2025 年 7 月 31 日（GLOBE NEWSWIRE）-- MiNK Therapeutics, Inc.（納斯達克：INKT），一家臨牀階段的生物製藥公司，正在開創全異體、現成的、不變自然殺傷 T 細胞（iNKT）療法的發現、開發和商業化，以治療癌症和"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/251021778.md"
published_at: "2025-07-31T13:37:10.000Z"
---

# MiNK Therapeutics 將發佈公司最新動態及 2025 年第一季度財務報告

> 紐約，2025 年 7 月 31 日（GLOBE NEWSWIRE）-- MiNK Therapeutics, Inc.（納斯達克：INKT），一家臨牀階段的生物製藥公司，正在開創全異體、現成的、不變自然殺傷 T 細胞（iNKT）療法的發現、開發和商業化，以治療癌症和

NEW YORK, July 31, 2025 ( GLOBE NEWSWIRE ) -- MiNK Therapeutics, Inc. ( NASDAQ: INKT ) , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T ( iNKT ) cell therapies to treat cancer and ...

### Related Stocks

- [INKT.US - MiNK Therapeutics](https://longbridge.com/zh-HK/quote/INKT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Mink Ventures Launches Drilling at Montcalm Nickel-Copper-Cobalt Project | Mink Ventures Corporation has initiated drilling at its Montcalm Nickel-Copper-Cobalt Project, following the completion  | [Link](https://longbridge.com/zh-HK/news/274666936.md) |
| MiNK Therapeutics Reports MiNK-215 Shows Strong Anti-Tumor Activity in Resistant Solid Tumors | MiNK Therapeutics Inc. has announced promising preclinical results for MiNK-215, a novel therapy targeting resistant sol | [Link](https://longbridge.com/zh-HK/news/266783933.md) |
| MiNK Therapeutics unveils promising results for agenT-797 in resistant cancers | MiNK Therapeutics has announced promising results for its investigational cell therapy, agenT-797, in treating resistant | [Link](https://longbridge.com/zh-HK/news/265134406.md) |
| MiNK Therapeutics Reports Durable Responses with Allo-iNKT Cell Therapy agenT-797 in Refractory Solid Tumors | MiNK Therapeutics Inc. reported updated clinical results for its allo-iNKT cell therapy, agenT-797, at the SITC Annual M | [Link](https://longbridge.com/zh-HK/news/264889429.md) |
| MiNK Therapeutics: Advancing Clinical Trials and Strategic Partnerships to Address GvHD and Pulmonary Diseases | Emily Bodnar from H.C. Wainwright maintains a Buy rating on MiNK Therapeutics with a $35 target, citing advancements in  | [Link](https://longbridge.com/zh-HK/news/265964329.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。